Tag:
Matt Emmens
Latest Headlines
Latest Headlines
Interview: Vertex CEO concerned about investors' 'hyper-focus' on hep C
Matthew Emmens
On the heels of Vertex Pharmaceuticals' ( $VRTX ) big news last week about changing CEOs next year, FierceBiotech chatted with both current chief executive Matt Emmens
Vertex CEO Emmens rolls out his five-year plan
Vertex's late-stage program for the hepatitis C drug telaprevir has absorbed a huge amount of revenue in recent years. The developer, which also believes it's on track to get an approval for a new
